• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Nature reviews. Urology >Prostate cancer: 'Galectin signature' reveals gal-1 as key player in angiogenesis
【24h】

Prostate cancer: 'Galectin signature' reveals gal-1 as key player in angiogenesis

机译：前列腺癌：“ Galectin标记”揭示gal-1是血管生成的关键因素

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

A research team comprising investigators from Argentina, France and the USA has identified a unique expression profile of galectins that can delineate the different stages of prostate cancer progression. Based on their initial findings, they were able to pinpoint a specific role for galectin-1 (gal-1) in neovascularization, and suggest it might be an attractive therapeutic target. The results of their collaborative effort are published in Cancer Research.Galectins are a family of glycan-binding proteins with known roles in tumour cell proliferation and invasiveness; a number of family members have previously been implicated in prostate cancer. "Despite considerable progress in identifying the roles of individual galectins in tumour biology, an integrated portrait of the galectin network in the prostate cancer tumour microenvironment is lacking," says Gabriel Rabinovich, corresponding author.
机译：由来自阿根廷，法国和美国的研究人员组成的研究小组确定了半乳糖凝集素的独特表达特征，可以描述前列腺癌进展的不同阶段。根据他们的初步发现，他们能够确定半乳凝素-1（gal-1）在新血管形成中的特定作用，并暗示它可能是有吸引力的治疗靶标。他们合作的结果发表在《癌症研究》上。Galectins是一类聚糖结合蛋白，在肿瘤细胞的增殖和侵袭中起着已知的作用。以前，许多家庭成员都与前列腺癌有关。通讯作者加布里埃尔·拉比诺维奇（Gabriel Rabinovich）说：“尽管在鉴定单个半乳凝素在肿瘤生物学中的作用方面取得了相当大的进步，但缺乏对半乳凝素网络在前列腺癌肿瘤微环境中的完整描述。”

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号